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Abstract
Background: In Ethiopia, the incidence of new cases of breast cancer is currently increasing resulting to high rates
of morbidity and mortality. Breast cancer is by far the most common cancer accounting for more than one out of
three cancer cases in women and one out of every five in the general population. The study was conducted in
University of Gondar Hospital cancer center, located in the North-West Ethiopia; to evaluate the clino-pathologic
characteristics of breast cancer and care provided for patients.
Methods: All biopsy proven breast cancer patients treated between 2016 and 2017, were identified and
information regarding histology, stage, therapeutic procedure and follow up was retrospectively collected from
their individual medical records and descriptive analysis was done.
Results: Among 82 patients treated, 67 (82%) were women and 15 (18%) were men. The median age at the time
of diagnosis was 45 years (25–82 years). Operation was performed for 56 (68%) patients. The predominant histology
was ductal carcinoma in 61 patients (74%), followed by breast carcinoma of No Special Type (NST) in 17 (21%). The
late presentation of the patients and the advanced stage at the time of presentation was observed in most of the
patients. Chemotherapy was administered in 79 (96%) patients. Radiotherapy was not available in the hospital.
Conclusion: Breast cancer incidence is rising and becoming a major public health problem in Northern Ethiopia.
Breast cancer care in northern-Ethiopia is limited in terms of both pathology, imaging and the offered treatment
modalities, which need to be improved.
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Background
Breast cancer is the most frequently occurring cancer in
women, with approximately 1.7 million new cases and
nearly 522,000 related deaths worldwide in 2012 [1]. In
Ethiopia the incidence of new cases of breast cancer is
currently increasing and has become one of the most
common cancer types causing high rates of morbidity
and mortality [2–4]. According to the study by Memirie
et al. breast cancer is the most common cancer, consti-
tuting 33% of the cancers in women and 23% of all can-
cers in Ethiopia. The Estimated national Age
Standardized Incidence rate for women was about 43
per 100,000 population [5].
The recently reported, first data from the Addis Ababa
City Population based cancer registry shows that breast
cancer is the most common cancer in women and one
of the top Ten cancers in men. Breast cancer incidence
has shown a steady yearly growth at the Tikur Anbessa
Specialized Hospital, the only hospital in the country
where cancer patients have access to oncology care [6,
7]. Furthermore, the majority of patients have at the
time of presentation advanced disease with 67% pre-
sented with locally advanced and 25% metastatic disease
[8]. The combination of all the aforementioned factors
leads to unsatisfactory treatment outcomes [8, 9].
The Ethiopian government has recognized this as a
major problem and has set a priority the advancement
of cancer care in the country. In 2015 the Ethiopian
healthcare authorities developed a cancer control plan,
which is focusing on the prevention as well as the gen-
eral improvement of cancer care in the country [10, 11].
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One of the most significant steps taken was the estab-
lishment of 6 specialized cancer centers at the teaching
university hospitals of Gondar, Hawassa, Mekelle,
Jimma, Haramaya and St. Paul’s Hospital [12].
Cancer care at the university hospital of Gondar
The University of Gondar Hospital is a tertiary teaching
hospital, located in the North-West Ethiopia providing
healthcare for a population of approximately 5,000,000
people. The hospital has around 600 beds with 400,000
patients treated annually. The hospital has more than
sixty years’ experience in teaching, research, health care
delivery and other community services employing 250
general practitioners, 20 internal medicine specialists, 14
surgeons, 12 pediatricians, 7 gynecologists and more
than 30 other medical specialists. The University Hos-
pital also has more than Ten years of experience and
participation in clinical trials focusing mainly on infec-
tious diseases such as leishmania and HIV infection [13,
14]. Until recently however, specialized and comprehen-
sive cancer care was not offered at the hospital, with just
selected cases being operated on and with the bulk of
diagnostic and interventional procedures being referred
to the Tikur Anbessa Specialized Hospital located 900
km from Gondar.
In January 2015 the Gondar University Hospital to-
gether with the BEZA Association of Switzerland, estab-
lished the first cancer treatment center in the region
[15]. The center includes Ten beds for outpatients as
well as an in-patient care unit with Eight trained nurses,
Two general practitioners and One senior oncology resi-
dent from the Tikur Anbessa Hospital on a monthly rota-
tion. Furthermore, a senior oncologist from Switzerland
regularly visits the center. One of the major achievement
of the center was the establishment of a regular multidis-
ciplinary tumor board consisting of a group of medical
professionals including a pathologist, a radiologist, a sur-
geon and the attending physician.
The histopathological evaluation is limited on the
morphology, with immunohistochemistry and other mo-
lecular tests currently unavailable. The department of
radiology is equipped with a CT-Scanner, an X-ray ma-
chine and Ultrasound devices. The University of Gondar
Hospital cancer center provides medical oncology ser-
vice such as the administration of chemotherapy and
hormone therapy for several tumor entities. Radiother-
apy is still not available at the center and those patients
requiring radiotherapy are referred to Tikur Anbessa
Hospital in Addis Ababa.
Breast cancer is one of the most common cancer en-
tities treated at the University of Gondar Hospital, there-
fore a retrospective evaluation was conducted to detect
patterns of care and evaluate early results [16].
Methods
The medical record review was done by physicians
working in the center. First, we have retrieved medical
records of all breast cancer patients. Secondly, we have
reviewed records and identify variables that can be ex-
tracted from the record. The completeness of the record
was ascertained by the primary investigator. Data was
collected on tumor stage, lymph node status, and pres-
ence of metastasis. The staging in Gondar University
Hospital is based on the presence or absence of symp-
toms and clinical evidence of the disease. In addition to
the clinical evaluation, every patient with locally ad-
vanced disease was evaluated at least with a chest x-ray
and abdominal ultrasound. Patients were staged accord-
ing to the TNM staging system of the American Joint
Committee on Cancer (AJCC), seventh edition [17]. The
date of morphological confirmation of breast cancer was
considered as date of diagnosis. Pretreatment evaluation
included evaluation of complete blood count, renal func-
tion tests and liver function tests. In addition to staging
data, we have collected data on therapeutic procedures
and follow-up. The study was conducted according to
the local ethical guidelines.
Result
From December 2016 to November 2017, 82 patient
were treated at the center. Sixty-seven patients (n:67,
82%) were females and 15 male (n:15, 18%). The median
age for all patients was 45 years (range from 25 to 82
years). About 47% of the patients were 40 years old or
less, 27% between 40 to 50 years of age and the rest 26%
were above age 50. Of the 67 female patients 38 patients
(57%) were premenopausal and 29 patients (43%) were
post-menopausal. The 15 male patients were generally
older than their women counterparts with a median age
of 65 (range 40 to 82 years). The age distribution is
depicted in Table 1.
The main presenting symptoms at presentation was a
longstanding breast mass in 65 patients (79%) and breast
ulceration in 15 patients (18%). Only one patient re-
ported breast pain as initial symptom and one patient
presented with pain outside of the breast. In 48 patients
(59%) the lesion was in the right breast, in 32 patients
(39%) in the left breast and 2 patients (2%) had bilateral
breast lesions. The median duration from first symptom
to the time of diagnosis was twelve months (range 3
weeks to 5 year) (Table 1).
All of the patients had a metastatic work up at least
with Chest X-Ray and abdominal Ultrasound. One of
the 82 patients had a mammography as initial work-up
and 23 (28%) of the patients had a breast ultrasound.
Fifty-six (68%) patients received an operation, the most
common surgical procedure was modified radical mast-
ectomy (n = 51), followed by simple mastectomy (n = 2)
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and palliative mastectomy (n = 3). Surgery was omitted
in 26 (32%) patients due to the advanced stage of the
disease with metastasis at presentation (Table 1)
The predominant histology was ductal carcinoma in
61 patients (74%), followed by breast carcinoma of No
Special Type (NST) in 17 (21%) patients. Ductal Carcin-
oma In-Situ (DCIS), lobular carcinoma, mucinous car-
cinoma and papillary carcinoma were found in one
patients each. The grade of differentiation was well dif-
ferentiated in 14 (17%), moderately differentiated in 30
(37%), poorly differentiated in 26(32%) and unknown in
12 (15%) patients. Surgical margin status was reported
for 29 patients, with 23 patients having surgical margins
free of tumor and 6 infiltrated by the tumor. Since the
immunohistochemistry tests are not fully installed in the
hospital, only 2 patients had tests for hormonal status
(expression of estrogen and progesterone receptors) to
which both were found to be positive (Table 1).
The stage at presentation was locally advanced or
metastatic for most of the patients. Distribution accord-
ing to stage at presentation is plotted on Table 1.
All but three patients (96%) received chemotherapy. Of
those 50 patients (61%) received Adriamycin and Cyclo-
phosphamide (AC-regimen), 14 patients (17%) Fluoroura-
cil, Adriamycin and Cyclophosphamide (FAC-regimen),
and 13 patients (16%) Adriamycin and Cyclophosphamide
plus Paclitaxel (AC-Taxol regimen). Cyclophosphamide,
Methotrexate and Fluorouracil (CMF-regimen) and Fluo-
rouracil, Adriamycin and Cyclophosphamide (FAC-regi-
men) were each administered in one patient each. Among
the patients who completed a full course of chemotherapy,
24 patients received empiric hormonal therapy and 22 pa-
tients did not receive any hormonal treatment. The rest of
the patients were on chemotherapy treatment. The sum-
mary of the clinical and pathologic characteristics of pa-
tients treated in University of Gondar hospital cancer
center is shown in Table 1.
Discussion
Most of the patients treated at the Gondar university
hospital cancer center were young with almost half of
them being less than 40 years old. This finding is similar
to the reports of previous breast cancer studies com-
pleted in Ethiopia [7, 9, 18–20]. This however, is
Table 1 Clinical and pathological characteristics of the patients
Characteristics Number Proportion
Total Population 82 100%
Duration of symptoms in months
≤ 4 8 10%
5–8 20 24%
9–16 28 34%
17–24 15 18%
≥ 25 11 13%
Menopausal Status (Women Only)
Pre-menopausal 38 57%
Post-menopausal 29 43%
Main presenting Symptom
Breast pain 1 1%
Breast Swelling 65 79%
Pain outside breast 1 1%
Ulceration 15 18%
Lateralization
Right Breast 48 59%
Left Breast 32 39%
Bilateral 2 2%
Type of Surgery performed
Surgery was not performed 26 32%
Modified Radical Mastectomy 51 62%
Simple Mastectomy 2 2%
Palliative Mastectomy 3 4%
Histology
Ductal Carcinoma 61 74%
Breast Cancer NST 17 21%
DCIS 1 1%
Lobular Carcinoma 1 1%
Mucinous Carcinoma 1 1%
Papillary Carcinoma 1 1%
Grade of Differentiation
G-1 14 17%
G-2 30 37%
G-3 26 32%
Not reported 12 15%
First-line chemotherapy Given
AC 50 61%
FAC 14 17%
AC + taxol 13 16%
Chemotherapy not started 3 4%
CAF 1 1%
CMF 1 1%
Table 1 Clinical and pathological characteristics of the patients
(Continued)
Characteristics Number Proportion
Hormonal Therapy
Anastrazole 6 7%
No hormonal therapy 22 27%
On Chemotherapy 36 44%
Tamoxifen 18 22%
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different from the current trend in western countries
where only less than 7% of the patients diagnosed are
younger than 40 years of age [21, 22]. The reason for the
high number of younger patients in Ethiopia is currently
unclear. A potential explanation for this is possibly the
demographics of Ethiopia and the high percentage of
younger individuals in the population of the country [18,
23]. Indeed, this is a logical explanation since reports in
our findings and other previous studies were not age ad-
justed. Nevertheless, several studies have shown that tu-
mors arising in younger patients are more aggressive
and those patients are at a higher risk of relapse and
death not only due to their age but also due to the
unique tumor biology [24–26]. Therefore, further re-
search is required to identify or exclude potential under-
lying genetic or environmental factors that would render
women in Ethiopia more prone to develop the disease at
a young age.
Another finding of our study is the high proportion of
male breast cancer, which accounts for 18% of the total
patient population during a calendar year. Unlike breast
cancer in women, the median age of breast cancer in
men in our findings is similar to the median age re-
ported in western countries [27]. A similar percentage of
male breast cancer patients was reported from this hos-
pital in 2016, with breast cancer being among the top 10
cancers diagnosed in men [16]. The rarity of the disease
worldwide which accounts for less than 1% makes this
finding interesting [27]. The reason/s for the higher inci-
dence of male breast cancer is not clear. A possible ex-
planation for this are unique cultural factors and/or
economic reasons that would explain why men seek
healthcare in rural Ethiopia more often than women do
[28]. However, reports from the Addis Ababa city popu-
lation based cancer registry, which includes mostly
urban population shows a higher proportion of male
breast cancer cases, of about 7% and still one of the top
10 cancers in men [2]. In conclusion, other possible en-
vironmental or genetic factors might be implicated in
the high incidence of male breast cancer in Ethiopia.
Considering the fact that the higher percentage of male
breast cancers is encountered in other Sub-Saharan
countries as well as blacks living in the United States
where the higher male-to-female ratio is also seen, it is
possible that a yet unknown genetic component is po-
tentially instrumental for this phenomenon [29]. Since
male breast cancer biology or treatment is not well
understood due to its rarity, Ethiopia could be one of
the study sites for future clinical trials to boost our
knowledge on the topic.
The other findings of our study is the late presentation
of the patients and the advanced stage at the time of
presentation. About 85% of the cases were diagnosed at
a stage III and IV. This finding was similar with previous
breast cancer studies from Ethiopia and other African
countries such as Tanzania, Uganda and Egypt [7, 9, 30–
32]. The absence of screening combined with the low
rate of cancer awareness and unavailability of
multi-modality treatment may be the reason for the late
presentation and diagnosis at an advanced disease stage.
It is obvious that the late stage at presentation negatively
affects the breast cancer survival [33]. As it was clearly
shown on the recent publication of Weiner et al., the
average survival probability of metastatic breast cancer
in Ethiopia was about 12 months which was significantly
lower than western countries [34]. Together with lack of
standard therapy, late stage at presentation could be one
of the reasons for the higher mortality rates attributed to
breast cancer patients [34]. Although the incidence rate
of breast cancer is lower in Africa than in high income
countries, there is a disproportionately higher number of
mortality [35, 36]. The age-standardized breast cancer
incidence rate is 70.08 in Europe and 28.66 in Africa,
while the mortality rate is about 15.93 in Europe and
13.72 in Africa [37, 38]. The five-year survival rates is
around 80% in the high-income countries and 40% in
the low-income countries [39]. The higher mortality
rates for breast cancer in Africa and other LMICs, is due
to the rising incidence as well as late-stage diagnoses
and limited access to treatment [40].
The major limitation of the present study is its small
sample size. The total number of patients treated in the
center could be relatively smaller compared to the total
population in the area. This could be due to lack of
awareness of the population, seeking of alternative trad-
itional treatments or limitation of knowledge and diag-
nostics facilities from health care providers. The other
reasons could be due to lack of information and thus,
less referral of the diagnosed or surgically treated pa-
tients to the center as it was newly established.
We believe that the strength of the study could be in-
creased if it had been possible to show the outcome of
the breast cancer patients in the hospital in terms of
overall survival or progression free survival. Our reason
for not including survival analysis was that, the medical
record of patients existing during the study period didn’t
have detailed address or phone number of the patients
which makes it difficult to get vital status. In spite of
these limitations, our first report on breast cancer clin-
ical, pathologic and treatment pattern may have an im-
pact in sensitizing third parties and thus ultimately
improving the healthcare offered. It could also be the
base for future larger studies.
Conclusion
Breast cancer incidence is rising and becoming a major
public health problem in Northern Ethiopia. Breast can-
cer care in northern-Ethiopia is limited in terms of both
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pathology, imaging and the offered treatment modalities,
which need to be improved. Furthermore, Ethiopia could
potentially become one of the major research areas in
terms of younger individuals and men with diagnosed
breast cancer.
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